Akari Therapeutics Plc (AKTX)
11.08
+2.07
(+22.97%)
USD |
NASDAQ |
Aug 28, 16:00
10.95
-0.13
(-1.17%)
After-Hours: 20:00
Akari Therapeutics Cash from Operations (Quarterly) : -3.112M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -3.112M |
| March 31, 2026 | -2.484M |
| December 31, 2025 | -3.039M |
| September 30, 2025 | -2.102M |
| June 30, 2025 | -3.302M |
| March 31, 2025 | -2.15M |
| December 31, 2024 | -2.124M |
| September 30, 2024 | -1.49M |
| June 30, 2024 | -4.894M |
| March 31, 2024 | -4.044M |
| December 31, 2023 | |
| September 30, 2023 | |
| June 30, 2023 | |
| March 31, 2023 | -4.88M |
| December 31, 2022 | |
| September 30, 2022 | |
| June 30, 2022 | -8.574M |
| March 31, 2022 | -5.050M |
| December 31, 2021 | -5.004M |
| September 30, 2021 | -1.559M |
| June 30, 2021 | -4.866M |
| March 31, 2021 | -7.418M |
| December 31, 2020 | -4.233M |
| September 30, 2020 | -0.7042M |
| June 30, 2020 | -4.274M |
| Date | Value |
|---|---|
| March 31, 2020 | -7.740M |
| December 31, 2019 | -3.464M |
| September 30, 2019 | -4.910M |
| June 30, 2019 | -4.772M |
| March 31, 2019 | 0.2289M |
| December 31, 2018 | -4.567M |
| September 30, 2018 | -5.331M |
| June 30, 2018 | -8.284M |
| March 31, 2018 | -4.398M |
| December 31, 2017 | -8.517M |
| September 30, 2017 | -9.214M |
| June 30, 2017 | -4.699M |
| March 31, 2017 | -9.168M |
| December 31, 2016 | -6.388M |
| September 30, 2016 | -4.999M |
| June 30, 2016 | -6.072M |
| March 31, 2016 | -7.060M |
| December 31, 2015 | -6.757M |
| September 30, 2015 | 5.172M |
| June 30, 2015 | -1.316M |
| March 31, 2015 | -2.064M |
| December 31, 2014 | |
| September 30, 2014 | |
| June 30, 2014 | |
| March 31, 2014 |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| DBV Technologies SA | -52.52M |
| Cellectis SA | -14.34M |
| argenx SE | -- |
| Autolus Therapeutics Plc | -25.16M |
| Evaxion AS | -- |
Cash from Operations (Quarterly) Related Metrics
| Cash from Financing (Quarterly) | 8.034M |
| Free Cash Flow | -10.74M |
| Free Cash Flow Per Share (Quarterly) | -1.737 |
| Free Cash Flow to Equity (Quarterly) | -3.073M |
| Free Cash Flow to Firm (Quarterly) | -3.032M |
| Free Cash Flow Yield | -71.03% |